Comment on: Pharmacokinetics and Safety of Recombinant Human Interleukin-1 Receptor Antagonist GR007 in Healthy Chinese Subjects
- 10 Downloads
Interleukin-1 (IL-1), a proinflammatory cytokine observed in the serum and synovial fluid in rheumatoid arthritis (RA) patients, has been implicated in the debilitating pathology that ultimately leads to the severe impairment and destruction of articular cartilage in RA patients . This observation led to the development and approval of anakinra, a IL-1 receptor antagonist which blocks the biological activity of the IL-1 endogenously secreted in human tissues and organs in RA patients by binding to the IL-1 receptor site [2, 3]. The effectiveness of anakinra has been shown not only in RA patients but also in patients with other neonatal inflammatory diseases [4, 5].
In this context, GR007, a novel recombinant human interleukin-1 receptor antagonist with amino-acid structural features consistent with those of anakinra , is being developed as a means to competitively restrict the interaction of the endogenous IL-1 in both chemotherapy-induced neutropenia and...
Compliance with Ethical Standards
No funding was used to prepare this letter.
Conflict of interest
The author has no conflict of interest.
- 2.Cohen S, Hurd E, Cush J. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(3):614–24.CrossRefGoogle Scholar
- 9.Wang X, Gao J, Qian L. Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis. Anticancer Drugs. 2015;26(1):35–45.Google Scholar